Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

The Potential of Procalcitonin as a Biomarker in Exacerbations of COPD

Author(s): Moises Rodriguez and Joseph Varon

Volume 19, Issue 2, 2023

Published on: 06 June, 2023

Page: [83 - 84] Pages: 2

DOI: 10.2174/1573398X1902230606164833

Open Access Journals Promotions 2
« Previous Next »
[1]
Hamade B, Huang DT. Procalcitonin: Where Are We Now? Crit Care Clin 2020; 36(1): 23-40.
[http://dx.doi.org/10.1016/j.ccc.2019.08.003]
[2]
Cano A, Turowski P, Ettcheto M. Duskey JT, Tosi G, Sánchez-López E, García ML, Camins A, Souto EB, Ruiz A, Marquié M, Boada M. Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges. J Nanobiotechnology 2021; 19(1): 122.
[http://dx.doi.org/10.1186/s12951-021-00864-x]
[3]
Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341(8844): 515-8.
[4]
Leli C, Cardaccia A, Ferranti M. Cesarini A, D'Alò F, Ferri C, Cenci E, Mencacci A. Procalcitonin better than C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in predicting DNAemia in patients with sepsis. Scand J Infect Dis 2014; 46(11): 745-52. Epub 2014 Sep 8.
[http://dx.doi.org/10.3109/00365548.2014.936493]
[5]
Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36(3): 941.
[http://dx.doi.org/10.1097/CCM.0B013E318165BABB]
[6]
Christ-Crain M, Jaccard-Stolz D, Bingisser R. Gencay MM, Huber PR, Tamm M, Müller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363(9409): 600.
[http://dx.doi.org/10.1016/S0140-6736(04)15591-8]
[7]
Schuetz P, Christ-Crain M, Thomann R. Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B, ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302(10): 1059.
[http://dx.doi.org/10.1001/jama.2009.1297]
[8]
Schuetz P, Wirz Y, Sager R. Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, Kristoffersen KB, Burkhardt O, Welte T, Schroeder S, Nobre V, Wei L, Bucher HC, Annane D, Reinhart K, Falsey AR, Branche A, Damas P, Nijsten M, de Lange DW, Deliberato RO, Oliveira CF,Maravić-StojkovićV, Verduri A, BeghéB, Cao B, Shehabi Y, Jensen JS, Corti C, van Oers JAH, Beishuizen A, Girbes ARJ, de Jong E, Briel M, Mueller B. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 2018; 18(1): 95. Epub 2017 Oct 13
[http://dx.doi.org/10.1016/S1473-3099(17)30592-3]
[9]
Schuetz P, Wirz Y, Sager R. Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, Kristoffersen KB, Burkhardt O, Welte T, Schroeder S, Nobre V, Wei L, Bucher HC, Bhatnagar N, Annane D, Reinhart K, Branche A, Damas P, Nijsten M, de Lange DW, Deliberato RO, Lima SS, Maravić-StojkovićV, Verduri A, Cao B, Shehabi Y, Beishuizen A, Jensen JS, Corti C, Van Oers JA, Falsey AR, de Jong E, Oliveira CF, Beghe B, Briel M, Mueller B. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10: CD007498. Epub 2017 Oct 12
[http://dx.doi.org/10.1002/14651858.CD007498.pub3]
[10]
Soler N, Torres A, Ewig S. Gonzalez J, Celis R, El-Ebiary M, Hernandez C, Rodriguez-Roisin R. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498-505.
[http://dx.doi.org/10.1164/ajrccm.157.5.9711044]
[11]
Daniels JM, Schoorl M, Snijders D. Knol DL, Lutter R, Jansen HM, Boersma WG. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010; 138(5): 1108. Epub 2010 Jun 24
[http://dx.doi.org/10.1378/chest.09-2927]
[12]
Jafari Nejad S, Behzadi A, Shafiepour M, Dalfardi B. Ahmad, Langari A, Ahmadipour H, Shafahi A and Fekri MS. Comparison of Serum Procalcitonin Levels between Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and Patients with Chronic Obstructive Pulmonary Disease. Curr Respir Med Rev 2023.

Rights & Permissions Print Cite
Article Metrics
14
4
Wayfinder Image
Open Access Journals Promotions
World Pneumonia Day
© 2024 Bentham Science Publishers | Privacy Policy